The number of infused CD34 cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1189-1196

  Tsirigotis, P ^a   Shapira, M Y ^a   Or, R ^a   Bitan, M ^a   Samuel, S ^a   Gesundheit, B ^a   Ackerstein, A ^a   Abdul Hai, A ^a   Slavin, S ^a   Resnick, I B ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOSPORIN A; FLUDARABINE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CELL COUNT; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; AGE; ALLOTRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; SEX DIFFERENCE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; CELL COUNT; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SEX FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955013940     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.331     Document Type: Article

References (28)

1. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664. (Pubitemid 36025282)
2. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of stem cells matter? Blood 2001; 98: 2900-2908.
3. Blaise D, Kuentz M, Fontanier C, Bouhris JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
4. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288-4290.
5. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graftversus- host disease without improved survival. Biol Blood Marrow Transplant 2007; 13: 1461-1468.
6. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza Jr FR, Ringdén O et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-4880.
7. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
8. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral blood stem cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
9. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
10. Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukaemia undergoing autologous transplantation. Bone Marrow Transplant 1995; 15: 907-913.
11. Barrett JA, Ringden O, Zhang MJ, Bashey A, Cahn JY, Cairo MS et al. Effect of nucleated cell dose on relapse and survival in identical twin bone marrow transplants for leukaemia. Blood 2000; 95: 3323-3327.
12. Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930-3934.
13. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
15. Przepiorka D, Smith TL, Folloder J, Khoury I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
16. Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS et al. Impact of ABO-incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 489-495.
17. Przepiorka D, Smith TL, Folloder J, Khoury I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
18. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bouhris JH et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after HLA identical sibling transplantation. Leukemia 2003; 17: 869-875.
19. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
20. Reisner Y, Gur H, Reich-Zeliger S, Martelli MF, Bachar- Lustig E. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann NY Acad Sci 2003; 996: 72-79.
21. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102: 1108-1113.
22. Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after non-myeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 822-828.
23. Panse JP, Heimfeld S, Guthrie KA, Maris MB, Maloney DG, Baril BB et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimerism and later clinical outcomes after nonmyeloablative conditioning. Br J Haematol 2005; 128: 659-667.
24. Gorin NC, Labopin M, Boiron JM, Theorin N, Littlewood T, Slavin S et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond- the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2006; 24: 3959-3966.
25. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
26. Ferrara JL. Pathogenesis of acute graft versus host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299-306.
27. Bacigalupo A, Lamparelli T, Gualandi F, Bregante S, Raiola AM, Di Grazia C et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002; 8: 656-661.
28. Spyridonidis A, Bertz H, Ihorst G, Grullich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (460 years) with active myeloid malignancies. Blood 2005; 105: 4147-4148.